Dinani apa kuti muwonetse zikwangwani ZANU patsamba lino ndikulipira kuti mupambane

Waya News

$100M Kuti Akhazikitse Chithandizo cha Ma Antibody Pamatenda Owopsa komanso Osowa Kwambiri Odziteteza

Written by mkonzi

Dianthus Therapeutics lero yalengeza kukwaniritsidwa kwa ndalama zake za $ 100 miliyoni Series A zotsogozedwa ndi 5AM Ventures, Avidity Partners, ndi Fidelity Management & Research Company, kutenga nawo gawo kuchokera kwa osunga ndalama owonjezera kuphatikiza Wedbush Healthcare Partners ndi oyambitsa oyambitsa Fairmount, Tellus BioVentures, ndi Venrock Healthcare Capital Partners. . Ndalamazi zidzagwiritsidwa ntchito kukulitsa utsogoleri ndi magulu asayansi, kupititsa patsogolo pulogalamu yotsogolera ya kampani, DNTH103, kupita kuchipatala chaka chino, ndikufulumizitsa mapulogalamu owonjezera otulukira anthu omwe ali ndi matenda oopsa komanso osowa kwambiri a autoimmune. DNTH103 ndi anti-monoclonal antibody yamphamvu, ya m'badwo wotsatira yomwe imayang'ana mwachisawawa mawonekedwe a C1 othandizira, zomwe zimapangitsa kuti pakhale kutsika kwa dosing komanso kuwongolera kocheperako komwe kumalimbikitsidwanso ndiukadaulo wowonjezera wa theka la moyo. 

Dianthus adalengezanso kusankhidwa kwa Marino Garcia ngati Purezidenti ndi Chief Executive Officer, kulowa nawo mu Novembala 2021, ndi Simrat Randhawa, MD, MBA, ngati Chief Medical Officer. Bambo Garcia, yemwe ndi katswiri wazamalonda komanso wodziwa bwino ntchito, amabweretsa zaka zoposa 25 zachitukuko cha bizinesi ndi maudindo a utsogoleri m'makampani apamwamba a biotech ndi pharma, posachedwapa monga Wachiwiri Wachiwiri kwa Purezidenti, Corporate and Business Development ku Zealand Pharma. Dr. Randhawa amabweretsa zaka zoposa 20 zachipatala ndi zochitika zamakampani opanga mankhwala kwa Dianthus, kuphatikizapo maudindo akuluakulu a utsogoleri omwe amayang'ana kwambiri m'malo a autoimmune komanso matenda osowa. Posachedwa adakhala Wachiwiri kwa Purezidenti wa Clinical and Medical Affairs ku Aurinia Pharmaceuticals.

"Tili odzipereka kupititsa patsogolo miyoyo ya anthu omwe ali ndi matenda oopsa komanso osowa kwambiri ndipo tili ndi chidaliro kuti ma antibodies athu omwe amasankha amatha kukhala ochiritsira kwambiri," adatero Marino Garcia, Purezidenti ndi Chief Executive Officer, Dianthus Therapeutics. "Ndife odala kukhala ndi gulu lamphamvu la osunga ndalama otsogola, mamembala odziwa bwino ntchito zama komiti, atsogoleri odziwa bwino ntchito ndi asayansi pamene tikupititsa patsogolo chipatala kumapeto kwa chaka chino, kupititsa patsogolo njira zomwe tatulukira, ndikukulitsa gulu lathu m'miyezi ikubwerayi. . Dianthus ali ndi mwayi wokhala kampani yotsogola, yam'badwo wotsatira motsogozedwa ndi kumvetsetsa kwakuzama kwa zosowa za odwala. ”

Dianthus imagwiritsa ntchito mphamvu ya kusankha mu njira zowonjezera kuti apange ma antibodies amphamvu a monoclonal omwe angathe kuthana ndi zofooka za chithandizo chamakono chothandizira. Mosiyana ndi machiritso amakono a antibody omwe amamangiriza ku mapuloteni omwe sagwira ntchito komanso ogwira ntchito, DNTH103 imangoyang'ana mawonekedwe a C1s omwe amathandizira puloteni, zomwe zimathandiza kuti mlingo wochepa wa dosing uchepetse komanso kuwongolera pafupipafupi. Ukadaulo wake wowonjezera wa theka la moyo umachepetsanso kuchuluka kwa dosing. Ndizikhalidwe zosiyanitsidwazi komanso kuletsa kwamphamvu kwa C1s, DNTH103 idapangidwa kuti ichepetse kulemedwa kwa kuchuluka kwambiri, kuwongolera pafupipafupi ndi kulowetsedwa kwa IV kapena kusokoneza, pafupipafupi kwa subcutaneous dosing. Kufulumizitsa chitukuko cha chithandizo chamankhwala chosavuta kutha kukhala chosinthika pakukulitsa kuchuluka kwa odwala omwe angapindule ndi chithandizo chothandizira, ndikuchepetsa kusapeza bwino komanso zosokoneza zomwe zafala m'miyoyo ya odwala masiku ano - pamapeto pake kulola odwala ambiri kukhala ndi moyo wathanzi mokwanira. kuthekera. 

"Ndife onyadira kuthandizira Dianthus Therapeutics popititsa patsogolo kupezeka ndi chitukuko chamankhwala am'badwo wotsatira, amphamvu, komanso osiyana kwambiri ndi othandizira othandizira," atero a Paula Soteropoulos, Director Board of Dianthus and Strategic Advisor ku 5AM Ventures. "Ndi utsogoleri wa Purezidenti ndi CEO wosankhidwa posachedwapa Marino Garcia, ndi gulu laluso la akatswiri odziwa sayansi ya sayansi ndi amalonda omwe ali ndi mbiri yopambana, tikuyembekeza kuwona Dianthus akubweretsa mankhwala awo atsopano kwa odwala omwe ali ndi vuto lalikulu komanso lachilendo. matenda a autoimmune."

Nkhani Zogwirizana

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Siyani Comment

Gawani ku...